louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00773305: Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer
Official title: Chart Review of the Efficacy of Prostate Seed Implantation for Local Control of Early Stage Prostate Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Keywords: seed implantation
Lead sponsor: Summa Health System
Sponsor class: OTHER
First posted: 2008-10-16
Enrollment: 200
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Prostate seed implantation for the treatment of early stage prostate cancer

Brief summary: The primary goal of this project is to evaluate the efficacy of prostate seed implantation for the treatment of early stage prostate cancer for patients treated at Summa Health System/Akron City Hospital and Salem Community Hospital.

Detailed description: Charts of early stage prostate cancer patients receiving prostate seed implants with or without external beam radiotherapy and/or hormonal therapy will be reviewed and abstracted. The abstracted data will include pathology reports including Gleason score and T stage, PSA, treatment assignment and dosimetry parameters including dose and percent compliant with established criteria based on guidelines established by the American Brachytherapy Society.

A database will be developed for capture of the abstracted data. Outcomes will be determined based on PSA levels at 2 and 5 years after prostate seed implantation. The role of hormonal therapy with prostate seed implantation and outcomes will be evaluated. The outcomes will be compared to national statistics.

Eligibility criteria: Inclusion Criteria:

* Prostate seed implantation for the treatment of early stage prostate cancer

Primary outcomes:
measure: To determine the efficacy of prostate brachytherapy for local control of early stage prostate cancer at Summa Health System
timeFrame: Pre-op through 4 follow-up visits
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Summa Health System
name: William Demas, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04899505: Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Official title: ODORAJA:Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Solid Tumor, Adult
Solid Tumor, Childhood
Chemotherapy Effect
Lead sponsor: Institut Curie
Sponsor class: OTHER
First posted: 2021-05-24
Enrollment: 27
Sex: ALL
Minimum age (years): 15
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients aged between 15 and 25 years with solid tumors

Brief summary: The appearance of unpleasant body odors in adolescent Young adult (aya) wille be evaluated undergoing chemotherapy


Eligibility criteria: Inclusion Criteria:

* Patients aged between 15 and 25 years;
* New patients treated at the Curie Institute and hospitalized in the AJA oncology department;
* Patient undergoing chemotherapy administered intravenously;
* Solid tumors.

Exclusion Criteria:

* Patient undergoing oral chemotherapy;
* Persons deprived of their liberty or under guardianship (including guardianship);
* Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Primary outcomes:
measure: Incidence of the development of unpleasant body odors in AYA oncology patients
timeFrame: 8 months
Secondary outcomes:
measure: Qualification of the smell and the discomfort felt
timeFrame: 8 months
measure: Quantification of the discomfort and the impact on quality of life
timeFrame: 8 months
measure: Identify possible causes of the appearance of these new body odors
timeFrame: 8 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut Curie
Study officials:
References:
Clinical trial NCT00489905: Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Official title: Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prostatic Neoplasms
Bone Density
Keywords: prostate cancer
bone mineral density
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: Baxter Healthcare Corporation
First posted: 2007-06-21
Enrollment: 24
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.


Eligibility criteria: Inclusion Criteria:

* Prostate cancer patients aged between 50-80 who is having or will have ADT. Baseline BMD in between -2 standard deviation (SD) and mean of that among young adults.

Exclusion Criteria:

* Patients with renal or liver problems, on calcium or other bisphosphonate therapy within six months before enrolling into the study.

Patients who have:

* Serum creatinine levels \>212 µmol/L (2.4 mg/dL).
* Creatinine clearance \<50 ml/min.
* WBC \<4.0x109/L, Hgb \<10 g/dL, platelets \<140x109/L. Patients with known hypersensitivity to bisphosphonates. Patients with history of diseases with influence on bone metabolism, such as Page's disease of bone, primary hyperparathyroidism or osteoporosis.

Primary outcomes:
measure: Bone mineral density of lumber spine
timeFrame: 12 months after administration of zolderonic acid
measure: Bone mineral density of femoral neck
timeFrame: 12 months after administration of zolderonic acid
Secondary outcomes:
measure: Change in serum creatinine, calcium, phosphate and alkaline phosphatase
timeFrame: From time of enrollment to 3 months after the last intervention
measure: Change in creatinine clearance
timeFrame: From time of enrollment to 3 months after the last intervention
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Department of Urology, Prince of Wales Hospital
Study officials:
affiliation: Department of Surgery, Division of Urology, The Chinese University of Hong Kong
name: Chi Fai Ng, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01847105: Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions
Official title: Assessing Patient Comfort in Silicone Hydrogel Contact Lenses When Cleaned and Stored in Two Different Multi-Purpose Disinfecting Solutions
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Contact Lens Solution Toxicity
Lead sponsor: Hom, Milton M., OD, FAAO
Sponsor class: INDIV
Collaborators: name: Abbott Medical Optics
First posted: 2013-05-06
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: Tolerability is compared between two Multi-purpose disinfecting solutions (MPDS).

Detailed description: According to recent surveys of contact lens fitters, the most prescribed treatments for contact lens dryness are: more frequent replacement schedule (24%), refit into different material (23%), rewetting drops (21%) and change care system (15%). Changing care systems has been a standard treatment for CL discomfort for many years. In the same survey, 30% of practitioners felt there is absolutely no difference among solutions with respect to reducing dryness and discomfort.

The investigators set out to compare the clinical performance of these two solutions: AMO's RevitaLens and Alcon's Opti-Free PureMoist.

Eligibility criteria: Inclusion Criteria:

1. Between the ages of 18 and over inclusive.
2. Males or females
3. Patient is in generally good \& stable overall health.
4. Patient likely to comply with study guidelines \& study visits.
5. Informed consent signed.
6. Are willing/able to return for all required study visits.
7. Are willing/able to follow instructions from the study investigator and his/her staff.
8. Have signed informed consent approved by Institutional Review Board or Independent Ethics Committee.

Exclusion Criteria:

1. Corneal refractive surgery within 6 months of this study.
2. Intra-ocular surgery within 6 months or ocular laser surgery within 6 months.
3. Ocular pathology (includes glaucoma and cataract), which could impact results and/or place patient at risk.

Primary outcomes:
measure: Self-reported comfort scores with contact lens care systems
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Azusa
country: United States
facility: Milton M. Hom, OD, FAAO
state: California
city: Morrow
country: United States
facility: Kirk L. Smick, OD, FAAO.
state: Georgia
city: Louisville
country: United States
facility: Ian Ben Gaddie, OD, FAAO.
state: Kentucky
Study officials:
name: Milton M Hom, OD FAAO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00349505: Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
Official title: Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Epithelial Ovarian Carcinoma
Figo Stage IIIC
Keywords: previous treatment surgery + 6 cycles of platinum based chemotherapy
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Sponsor class: OTHER
First posted: 2006-07-07
Enrollment: 67
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II to study results and morbidity of intra peritoneal hyper-thermic chemotherapy as consolidation therapy in patients with FIGO stage IIIC epithelial ovarian carcinoma treated by surgery and a total of 6 cycles of platinum based chemotherapy.

A second look operation is performed after treatment; during this second look secondary cytoreductive surgery is accepted without bowel resection.If none or milimetric peritoneal disease is obseved an intraperitoneal chemotherapy is achieve


Eligibility criteria: Inclusion Criteria:

epithelial ovarian carcinoma previous surgery + 6 cycles platinum based chemotherapy

-

Exclusion Criteria:

* Patients ASA 3 patients with no residual tumor at first operation negative microscopic second look

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Dominique ELIAS, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05887505: Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy
Official title: Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Hepatocellular Carcinoma
Liver Function
Postoperative Complications
Keywords: Vitamin D Supplementation
Hepatectomy
Perioperative
Lead sponsor: Taoyuan General Hospital
Sponsor class: OTHER_GOV
First posted: 2023-06-02
Enrollment: 120
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: High concentrations of parathyroid hormone (PTH) are common in patients with hepatocellular carcinoma (HCC). This study is aimed to investigate effects of vitamin D status and its multiple mega-dosage supplementation on PTH and clinical outcomes in HCC patients before and after hepatectomy. It's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. The subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.


Eligibility criteria: Inclusion Criteria:

* 1. ≥ 20-year HCC subjects receiving laparoscopic hepatectomy
* 2.Sign the informed consent

Exclusion Criteria:

* 1. Using estrogen drugs, bisphosphonates, or drugs for bone disease.
* 2. Consume calcium tablets within 2 weeks before operation
* 3. Sarcoidosis, multiple myeloma
* 4. Pregnant women or plan to become pregnant within 3 months after surgery
* 5. Autoimmune hepatitis (AIH)
* 6. Early liver recurrence
* 7. Used to participate in other clinical trials

Primary outcomes:
measure: Whether there is an association between 25(OH)D and PTH: positive or negative association , or no association
timeFrame: During the study period
measure: Ratio of liver failure
timeFrame: 7 days pre- OP (day -7)
measure: Ratio of liver failure
timeFrame: 1 day pre- OP (day -1)
measure: Ratio of liver failure
timeFrame: 1 day post- OP (day 1)
measure: Ratio of liver failure
timeFrame: 1 day before discharge
Secondary outcomes:
measure: 25(OH)D status
timeFrame: Baseline (day -7), day -1, day 1 and 1 day before discharge
measure: Prevalence of high PTH
timeFrame: Baseline (day -7), day -1, day 1 and 1 day before discharge
measure: Prevalence of hypercalcemia
timeFrame: Baseline (day -7), day -1, day 1 and 1 day before discharge
measure: Prevalence of hypomagnesemia
timeFrame: Baseline (day -7), day -1, day 1 and 1 day before discharge
measure: 30-day mortality
timeFrame: day 1 post-OP and 1 day before discharge
measure: Clinical outcomes
timeFrame: day 1 post-OP and 1 day before discharge
measure: Complications after surgery
timeFrame: day 1 post-OP and 1 day before discharge
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01121705: Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
Official title: Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Hepatitis
Keywords: genotype 3
Combination treatment
Short treatment
Lead sponsor: Casa Sollievo della Sofferenza IRCCS
Sponsor class: OTHER
First posted: 2010-05-12
Enrollment: 360
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with HCV genotype 3 infection.

Detailed description: Patients are randomized to standard length of treatment or to a variable duration: 12 weeks for patients with undetectable HCVRNA at week 4 or 24 or 36 weeks for those with detectable HCV RNA at week 4.

Eligibility criteria: Inclusion Criteria:

* Naive HCV patients
* HCVRNA positive
* Normal TSH
* ANA \<1:160

Exclusion Criteria:

* Portal hypertension
* Renal failure
* HBsAg or HIV
* Alcohol consumption \>30 g/day
* Active IV drug use
* Chronic systemic diseases

Primary outcomes:
measure: Sustained virological response (SVR)
timeFrame: 6 months after the end of treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Canossa
country: Italy
facility: Ospedale Civile
city: Casarano
country: Italy
facility: Ospedale Casarano
city: Castellana Grotte
country: Italy
facility: IRCCS "De Bellis"
city: Catania
country: Italy
facility: Ospedale "Garibaldi"
city: Rome
country: Italy
facility: Ospedale "S.Camillo"
city: Rome
country: Italy
facility: Università Cattolica Sacro Cuore Roma
city: Sassari
country: Italy
facility: Ospedale Civile
city: Venosa
country: Italy
facility: Ospedale Venosa
Study officials:
affiliation: IRCCS - San Giovanni Rotondo
name: Alessandra Mangia, MD
role: STUDY_DIRECTOR
References:
citation: Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008 Aug 15;28(4):397-404. doi: 10.1111/j.1365-2036.2008.03763.x. Epub 2008 Jun 11.
Clinical trial NCT06567405: Derma Pen as Treatment of Gingivitis Induced by Orthodontics
Official title: Impact of Derma Pen in the Treatment of Gingivitis Induced by Orthodontic Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gingivitis
Orthodontic Appliance Complication
Lead sponsor: Tanta University
Sponsor class: OTHER
First posted: 2024-08-22
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Although orthodontic therapy frequently improves tooth alignment and appearance, its problems with oral hygiene can make patients highly susceptible to gingivitis. After orthodontic treatment, gingivitis is a typical problem. New treatments that promote healing and decrease inflammation are needed. Ascorbic acid and Derma Pen used together have recently surfaced as a potentially effective therapy option for patients who seeking for periodontal therapy during and after orthodontic treatments.


Eligibility criteria: Inclusion Criteria:

1. patients age: 18-25 years .
2. systemically healthy patients.
3. mild to moderate plaque-induced gingivitis patients during orthodontic therapy

Exclusion Criteria:

1. periodontitis.
2. individuals who smoke or those who have tobacco related habits.
3. partially edentulous individuals.
4. individuals who are diagnosed with drug-induced gingival enlargement.
5. Pregnant or lactating women

Primary outcomes:
measure: gingival index (GI)
timeFrame: one month
Secondary outcomes:
measure: Plaque Index (PI)
timeFrame: one month
Other outcomes:
Locations:
city: Tanta
country: Egypt
facility: Tanta University
Study officials:
References:
Clinical trial NCT06164405: Arterial dP/dt Dependency on Loading Conditions
Official title: RESPONSE OF ARTERIAL dP/dt TO FLUIDS AND VASOACTIVE DRUGS DURING ABDOMINAL SURGERY: A PROSPECTIVE PILOT STUDY
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Intraoperative Hemodyamic Monitoring
Keywords: emodinamica
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2023-12-11
Enrollment: 88
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: surgical patients

Brief summary: In the present study the investigators aim to assess the changes of the arterial dP/dtmax induced by fluids and vasoactive drugs during abdominal surgery


Eligibility criteria: Inclusion Criteria:

patients scheduled for abdominal surgery informed consent acceptance

-

Exclusion Criteria:

* BMI\> 30 Kg /m2;
* Atrial Fibrillation;
* Congestive heart failure with FE \<35% and/or NYHA≥3;
* Severe known cardiac valve disease;
* Emergency surgery
* Shock or any acute conditions who required admission intensive care unit

Primary outcomes:
measure: dp/dt fluids dependency
timeFrame: intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Fondazione Policlinico Universitairo Agostino Gemelli
state: RM
Study officials:
References:
Clinical trial NCT01182805: Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function
Official title: Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Heart Failure, Diastolic
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Pixel Velocity, Inc. / Epsilon Imaging
name: National Heart, Lung, and Blood Institute (NHLBI)
First posted: 2010-08-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to evaluate a novel ultrasound system's ability to assess the relaxing properties of the heart compared to current techniques.


Eligibility criteria: Inclusion Criteria:

* Patients scheduled to undergo a clinically indicated left heart cardiac catheterization will be recruited for the study.

Exclusion Criteria:

* Suspected acute ST elevation myocardial infarction.
* Acute coronary syndrome with active ongoing chest pain
* Known or suspected acute aortic dissection
* Known or suspected cardiac tamponade
* Known history of unoperated constrictive pericarditis
* Known or suspected severe aortic stenosis or severe mitral regurgitation
* Heart rhythm other than sinus rhythm on pre-cath EKG
* Age \< 18 years old
* Unable to provide informed consent

Primary outcomes:
measure: Diastolic Circumferential Strain Rate During Isovolumic Relaxation
timeFrame: Assessed from echo obtained at time of enrollment
measure: Early Diastolic Mitral Annular Velocity (E-prime) Using Tissue Doppler
timeFrame: Assessed from echo obtained at time of enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Cardiovascular Center
state: Michigan
Study officials:
affiliation: University of Michigan
name: Theodore J Kolias, M.D.
role: PRINCIPAL_INVESTIGATOR
References: